Journal List > J Lung Cancer > v.8(2) > 1050712

J Lung Cancer. 2009 Dec;8(2):99-102. Korean.
Published online December 31, 2009.
©2009 Korean Association for the Study of Lung Cancer
Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma
Jae Jun Kim, M.D., Jae Kil Park, M.D., and Young Pil Wang, M.D.
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.

Address for correspondence: Jae Kil Park, M.D. Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 505, Banpo-dong, Seocho-gu, Seoul 137-701, Korea. Tel: 82-2-2258-6133, Fax: 82-2-594-8644, Email:
Received October 08, 2009; Revised November 06, 2009; Accepted November 13, 2009.



Incidence of peripheral squamous cell carcinoma (pSCCs) of the lung has increased over recent years, but the immunohistochemical factors involved in pSCCs have not been well established. The aim of this study was to analyze the immunohistochemical differences between pSCCs and central-type SCCs (cSCCs), and similarities between pSCCs and peripheral adenocarcinomas (pADCs).

Materials and Methods

In this retrospective study, we investigated the expression of three potential prognostic factors (p53, Ki-67, t-CEA), and two potential therapeutic targets (epidermal growth factor receptor [EGFR], and c-erbB-2) in 263 surgically resected cases of primary SCC and pADCs of the lung from January 2001 to July 2008. We divided the SCCs between peripheral and central types, and compared the expression rates of markers between pSCCs and cSCCs, and between pSCCs and pADCs.


In this study, there were 149 pADC cases, and among the 114 SCC cases, there were 41 pSCCs (36.0%). There were significantly higher expression rates of Ki-67 and EGFR in pSCCs than in cSCCs or pADCs (p=0.003, p=0.039, respectively).


We found immunohistochemical differencies in pSCCs from cSCCs and pADCs.

Keywords: Lung neoplasms; Immunohistochemical study; Malignant diseases


Table 2
Positive Rates of Various Tumor Markers and Statistical Differences among the Groups
Click for larger image

1. Hammar SP, Brambilla E, Pugatch B, et al. Squamous cell carcinoma. In: Travis WD, Brambilla E, Muller-hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press; 2004. pp. 26-30.
2. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 1996;111:1125–1134.
3. Tomashefski JF Jr, Connors AF Jr, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med 1990;114:468–474.
4. Funai K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 2003;27:978–984.
5. Kushihashi T, Munechika H. Histologic classification and radiologic manefestation of lung cancer. Jpn J Diagn Imaging 1994;16:379–390.
6. Takahasi T. Squamous cell carcinomas in the periphery of the lung: cell types and roentgenological findings. Jpn J Lung Cancer 1984;24:183–194.
7. Zwirewich CV, Vedal S, Miller RR, Müller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology 1991;179:469–476.
8. el-Torkey M, Giltman LI, Dabbous M. Collagens in scar in carcinoma of the lung. Am J Pathol 1985;121:322–326.
9. Tokuda H. Morphological features of peripherally originating squamous cell carcinoma of the lung. Jpn J Lung Cancer 1990;30:963–973.
10. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg 2004;78:222–227.
11. Demoly P, Pujol JL, Godard P, Michel FB. Oncogenes and anti-oncogenes in lung cancer. Presse Med 1994;23:291–297.
12. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998;16:1207–1217.
13. Osada H, Takahashi T. Pathophysiology of lung cancer. Saishin Igaku 1997;52:12–18.
14. Harpole DH Jr, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470–1476.
15. Sadoff L. The usefulness of carcinoembryonic antigen testing in the overall management of patients with non-small cell lung cancer. Am J Clin Oncol 1998;21:284–286.
16. Veronesi G, Pelosi G, Sonzogni A, et al. Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. Lung Cancer 2005;48:233–240.
17. Kern JA, Filderman AE. Oncogenes and growth factors in human lung cancer. Clin Chest Med 1993;14:31–41.